Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 6 Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 2 Small Cell Lung Carcinoma 2 Neoplasm Metastasis 2 Lung Neoplasms 2 Head and Neck Neoplasms 2 Non-Muscle Invasive Bladder Neoplasms 1 Myeloproliferative Disorders 1 Leukemia, Myeloid, Acute 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Laryngeal Diseases 1 Infections 1 Hematologic Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 COVID-19 1 Breast Neoplasms 1 Anemia, Refractory, with Excess of Blasts 1 Adenocarcinoma Of Esophagus 1

Interventions

Gemcitabine 30 Mitomycin 25 BCG Vaccine 13 Docetaxel 10 Epirubicin 6 erdafitinib 5 durvalumab 5 dodecyl maltoside 5 Radiotherapy 5 Cystoscopy 5 apaziquone 4 ALT-803 4 tislelizumab 3 5-aminolevulinic acid hexyl ester 3 viscum album peptide 2 pembrolizumab 2 disitamab vedotin 2 avelumab 2 VB4-845 2 Therapeutics 2 Imiquimod 2 Hyaluronic Acid 2 Administration, Intravesical 2 1-phenyl-3,3-dimethyltriazene 2 vocimagene amiretrorepvec 1 valrubicin 1 tremelimumab 1 toripalimab 1 pirarubicin 1 pemigatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Non-Muscle Invasive Bladder Neoplasms × monalizumab × Clear all

NCT06503614 2026-04-08

ENHANCE

Hoosier Cancer Research Network

Phase 2 Recruiting

Non-Muscle Invasive Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡